Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SRDX 
SurModics Inc (SRDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: SRDX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $43
1 Year Target Price $43
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 36.4% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 441.42M USD | Price to earnings Ratio - | 1Y Target Price 43 |
Price to earnings Ratio - | 1Y Target Price 43 | ||
Volume (30-day avg) 2 | Beta 1.32 | 52 Weeks Range 26.00 - 42.25 | Updated Date 07/13/2025 |
52 Weeks Range 26.00 - 42.25 | Updated Date 07/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -16.34% | Operating Margin (TTM) -5.38% |
Management Effectiveness
Return on Assets (TTM) -1.44% | Return on Equity (TTM) -16.96% |
Valuation
Trailing PE - | Forward PE 208.33 | Enterprise Value 443078341 | Price to Sales(TTM) 3.63 |
Enterprise Value 443078341 | Price to Sales(TTM) 3.63 | ||
Enterprise Value to Revenue 3.64 | Enterprise Value to EBITDA 179.57 | Shares Outstanding 14299300 | Shares Floating 12986879 |
Shares Outstanding 14299300 | Shares Floating 12986879 | ||
Percent Insiders 3.4 | Percent Institutions 84.22 |
Upturn AI SWOT
SurModics Inc
Company Overview
History and Background
SurModics, Inc. was founded in 1979. Initially focused on surface modification technologies, it evolved to provide in vitro diagnostics, and drug delivery technologies to the healthcare industry. Significant milestones include the development of various coating technologies and the acquisition of companies to expand its product offerings.
Core Business Areas
- Medical Device: Develops and manufactures surface modification technologies and polymer solutions for medical devices, improving device performance and patient outcomes. This includes coatings and drug delivery technologies.
- In Vitro Diagnostics: Provides components and reagents used in in vitro diagnostic assays, including immunoassay stabilizers and substrates, enabling reliable and accurate test results.
Leadership and Structure
The company is led by a CEO and has a structured organization with departments focusing on R&D, manufacturing, sales, and marketing. The Board of Directors provides strategic oversight.
Top Products and Market Share
Key Offerings
- Sereneu2122 Low Friction Coating: A lubricious coating technology used on medical devices like catheters and guidewires to reduce friction and improve deliverability. Competitors include Hydromer and AST Products, Inc. Revenue data specific to this product alone is not publicly available, but coatings are a substantial part of the medical device segment revenue.
- StabilZymeu00ae Immunoassay Stabilizers: Used in in vitro diagnostic assays to improve the stability and performance of antibodies and enzymes. Competitors include BBI Solutions and Meridian Life Science. Market share data specific to this product alone is not publicly available but it is an important part of their In-vitro diagnostics segment.
Market Dynamics
Industry Overview
The medical device and in vitro diagnostics industries are experiencing growth driven by increasing demand for advanced healthcare solutions, aging populations, and technological advancements.
Positioning
SurModics is positioned as a technology provider for medical device and diagnostic companies. Its competitive advantage lies in its proprietary surface modification and drug delivery technologies, and assay stabilization technologies.
Total Addressable Market (TAM)
The total addressable market (TAM) is estimated to be in the billions of dollars across the medical device coating and in vitro diagnostics reagents sectors. SurModics is positioned to capture a portion of this market through its product offerings and partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms
- Established relationships with medical device companies
- Expertise in surface modification and drug delivery
- Strong brand reputation
Weaknesses
- Dependence on key customers
- Limited manufacturing capacity compared to larger players
- Competition from larger, more diversified companies
Opportunities
- Expanding into new therapeutic areas
- Acquiring complementary technologies
- Increasing market penetration in emerging markets
- Capitalizing on the growing demand for minimally invasive procedures
Threats
- Increased regulatory scrutiny
- Technological obsolescence
- Pricing pressure from competitors
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- DSM (no US ticker)
- Hydromer (no US ticker)
- BBI Solutions (no US ticker)
Competitive Landscape
SurModics competes with companies of varying sizes, ranging from specialized technology providers to large, diversified corporations. Its competitive advantage lies in its niche expertise and proprietary technologies.
Major Acquisitions
Creagh Medical
- Year: 2022
- Acquisition Price (USD millions): 270
- Strategic Rationale: Expanded SurModics' offerings in the vascular space and enhanced its ability to provide complete solutions for medical device customers.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was driven by new product introductions, strategic acquisitions, and increasing demand for its technologies. Growth rates varied depending on market conditions and product development cycles.
Future Projections: Since SurModics is no longer publicly traded, no analyst projections are available.
Recent Initiatives: Recent initiatives included the development of new coating technologies and diagnostic reagents.
Summary
SurModics, formerly a strong player in the medical device coating and in vitro diagnostics space, was acquired and is no longer publicly traded. Prior to the acquisition, the company possessed proprietary technologies and strong customer relationships. Potential threats included regulatory changes and competition. With its strategic acquisitions, SurModics worked to expand its product offerings and market reach. The take-private transaction changes the landscape for future public investment and evaluation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (prior to acquisition)
- Industry reports
- News articles
- Company Website (prior to acquisition)
Disclaimers:
The information provided is based on publicly available data and is not intended as investment advice. Market share data is estimated and may not be precise. Financials are not available since the company has been acquired and taken private.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About SurModics Inc
Exchange NASDAQ | Headquaters Eden Prairie, MN, United States | ||
IPO Launch date 1998-03-04 | CEO, President & Director Mr. Gary R. Maharaj | ||
Sector Healthcare | Industry Medical Devices | Full time employees 389 | Website https://www.surmodics.com |
Full time employees 389 | Website https://www.surmodics.com | ||
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.